Scott Berger
Scott Berger
Scott J. Berger, a Sr. Manager within the Waters Biopharmaceutical Markets team at Waters, received his B.S. (Biochemistry) from the University of the Sciences in Philadelphia, and his Ph.D. (Chemistry/Biochemistry) from the University of Colorado at Boulder. His interests for combining high- resolution separations and mass spectrometry, started during his postdoctoral research under Dr. Richard D. Smith (PNNL), and continued while a Principal Scientist in the Life Sciences R&D group at Waters. His current technical focus within the Biopharmaceutical Business Group relates to the production of novel and robust bioseparations and LCMS workflows for the analysis of biotherapeutics.

Posts by author

Analytical Tools for Developing Biosimilars: Part 3, Glycosylation, Aggregation, and Charge Variants

By January 13, 2017

In biotherapeutics, the state of glycosylation has a direct and pronounced effect of the structure, stability, serum half-life, immunogeneicity and bioactivity of the molecule, and constitutes a critical quality attribute (CQA). In our study, characterizing and comparing the glycosylation profile of infliximab began by examining the glycosylation profiles from intact and reduced subunit mass data.

Categories: Pharmaceutical
Tags: , , , , , , , , , ,

Analytical Tools for Developing Biosimilars: Part 2, Peptide Analysis

By January 13, 2017

Advancements in High-Resolution Analytics for Characterization of Innovator and Biosimilar Therapeutics Part 2: Peptide Analysis of Infliximab

Categories: Pharmaceutical
Tags: , , , , , ,

How Analytical Technologies Support the Development of Biosimilar Drugs

By January 12, 2017

Advancements in High-Resolution Analytics for the Characterization of Innovator and Biosimilar Therapeutics As the pharmaceutical industry continues to evolve its focus from small-molecule drugs to balanced product portfolios that include protein therapeutics, analytical chemists are… Read more >

Categories: Pharmaceutical
Tags: , , , , , , , , , ,

An Inflection Point for Biopharmaceutical Host Cell Protein Analysis

By June 7, 2016

Has LC-MS Become a Generally Accepted Tool for Complementing Immunoassay-based HCP Analysis? My colleague Catalin Doneanu and I just returned from Lisbon, Portugal, where we attended the BEBPA Conference on Host Cell Protein (HCP) analysis.… Read more >

Categories: Pharmaceutical